 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...1112131415161718192021...143144» |
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2189;
P=N/A
HR 0.87 (95% CI 0.76- 0.99). Conclusions First-line treatment with CT alone compared with CT plus TT, show no detrimental effect in overall survival.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
The role of early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2176;
P=N/A
6.27% group vs. MSAF change < 6.27% group: 317 days vs. 217 days; HR:1.598, 95%CI:1.016-2.514, P=0.03). Conclusions The early changes in ctDNA levels after initiation of first-line chemotherapy in mCRC would enable early prediction of response prior to radiological assessment.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients: Results from the PETACC 8 study () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2151;
Conclusions Early CC patients with a high CM intake did not generally exhibit an impaired outcome, even though tolerability of adjuvant chemotherapy was reduced. Anticoagulation was the only CM category associated with a shorter DFS and OS.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Dynamics and processes in the perception of colorectal cancer patients facing skin toxicity due to an EGFR-inhibitor (Alicante Auditorium - Hall 10) - Jul 27, 2023 - Abstract #ESMO2023ESMO_1603;
The digestive oncologist, dermatologist and nurse specialist should take this into account when counselling these patients. Additionally, there is a lack of knowledge about the impact of this side effect by healthcare professionals.
- monalizumab (IPH2201) / AstraZeneca, Innate, Erbitux (cetuximab) / Eli Lilly, EMD Serono
INTERLINK-1: Phase III study of cetuximab (CTX) (Burgos Auditorium - Hall 3) - Jul 27, 2023 - Abstract #ESMO2023ESMO_1323;
P3
The safety profile was acceptable. ORR with P + CTX was higher than previous reports.
- MACH-EGFR: Individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab) in patients (pts) with locally advanced (LA) squamous cell carcinomas of head and neck (SCCHN) (Burgos Auditorium - Hall 3) - Jul 27, 2023 - Abstract #ESMO2023ESMO_1321;
60 years 1243 (40%) 1336 (44%) ECOG PS 0 1861 (60%) 2181 (72%) 1 1185 (38%) 847 (28%) 2 33 (1%) 4 (<1%) Location Larynx 691 (22%) 219 (7%) Hypopharynx 437 (14%) 295 (10%) Oral cavity 89 (3%) 185 (6%) Oropharynx 1875 (61%) 2329 (77%) p16 positive/negative/UK 631/413/831 1784/100/445 Stage (AJCC 7) I-II 67 (2%) 15 (<1%) III 552 (18%) 383 (13%) IV 2476 (80%) 2634 (87%) Median follow-up (years) 4.0 3.9 Number of deaths (% of pts) 1209 (39%) 798 (26%) Conclusions There was no survival benefit with the addition of Ab to LRT for either comparison. Importantly, replacing CT with anti-EGFR Ab, as systemic treatment added to LRT, results in inferior survival.
- Rechallenge with EGFR inhibitors in ctDNA RAS/BRAF wild type refractory metastatic colorectal cancer: Individual patients' data pooled analysis from 4 phase II trials (Burgos Auditorium - Hall 3) - Jul 27, 2023 - Abstract #ESMO2023ESMO_881;
P2
Conclusions Results of this individual patients' pooled analysis demonstrate promising clinical activity of rechallenge with EGFR inhibitors with nearly one-third of the pts experiencing long PFS that lead to prolonged survival. Thus, rechallenge with anti-EGFR-based strategies might be considered as a therapeutic option in the continuum of care of pts with refractory ctDNA RAS/BRAF wt mCRC.
- Keytruda (pembrolizumab) / Merck (MSD)
Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study (Burgos Auditorium - Hall 3) - Jul 27, 2023 - Abstract #ESMO2023ESMO_877;
P3
Thus, rechallenge with anti-EGFR-based strategies might be considered as a therapeutic option in the continuum of care of pts with refractory ctDNA RAS/BRAF wt mCRC. Pts were randomly assigned 1:1 to receive pembro 200 mg Q3W or chemo (mFOLFOX6 or FOLFIRI Q2W
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS/BRAF wild-type and left-sided metastatic colorectal cancer (mCRC): The DEEPER trial (JACCRO CC-13) (Burgos Auditorium - Hall 3) - Jul 27, 2023 - Abstract #ESMO2023ESMO_873;
P2
Background The DEEPER trial, which evaluated m-FOLFOXIRI (irinotecan 150 mg/m2, oxaliplatin 85 mg/m2, 5-FU 2400 mg/m2) plus cetuximab (cet) vs. bevacizumab (bev) as initial treatment in terms of depth of response (DpR) as the primary endpoint in RAS wild-type mCRC, has demonstrated a significantly better DpR of the cet arm (Tsuji A, et al...Conclusions m-FOLFOXIRI plus cet regimen could be a good option for upfront chemotherapy with high DpR and longer PFS in mCRC pts with RAS/BRAF wild-type and left-sided tumors. The benefit may be relevant for pts with extra-hepatic metastases or male.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX in RAS wild-type patients with initially unresectable colorectal liver metastases: The TRICE randomized clinical trial (Burgos Auditorium - Hall 3) - Jul 27, 2023 - Abstract #ESMO2023ESMO_872;
P2
Additionally, the triplet arm was associated with a higher incidence of grade 3-4 neutropenia (44.1% vs. 27.0%; P = .03) and diarrhea (5.9% vs. 0%; P = .03). Conclusions Although intensifying upfront systemic chemotherapy in RAS wild-type metastatic CRC patients offered a better depth of tumor response, there was an increase in neutropenia and diarrhea incidence with no significant difference in ORR, PFS, and R0 resection rate.
- Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab plus cetuximab in unresectable stage III or IV cutaneous squamous cell carcinoma: First results from the AliCe study (Le) - Jul 27, 2023 - Abstract #ESMO2023ESMO_640;
P2
Table: 1087MO Baseline characteristics and outcome data SAF set (n=51) PP set (n=37) Mean age (years) 71.8 73.2 Sex female 33.3% 32.4% ECOG > = 1 37.3% 43.2% Stage (III/IV) 21.6%/78.4% 24.3%/75.7% Anogenital primary 31.4% 21.6% Prior systemic treatment 66.7% 67.6% Response rate 45.1% 56.8% Median PFS (95% CI), months 8.4 (4.5-10.2) 9.2 (8.3-12.5) Median OS (95% CI), months 17.4 (11.1-33.1) 25.4 (13.9-NR) AE > = grade 2 43 (84.3%) 32 (86.5%) Adverse drug reactions (ADR) > = grade 3 10 (19.6%) 6 (16.2%) Conclusions Avelumab plus cetuximab is a feasible treatment option in patients with cSCC. This combination shows remarkable activity even in patients in whom PD-1 blockade has low efficacy, such as anogenital cSCC, or after failure of anti-PD-1 monotherapy.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A phase II study (Sevilla Auditorium - Hall 9) - Jul 27, 2023 - Abstract #ESMO2023ESMO_304;
P1/2
Conclusions Combination of D-1553 and cetuximab showed an acceptable safety profile and achieved a higher response rate than D-1553 monotherapy and a promising PFS in heavily pretreated pts with KRAS G12C mutated CRC. More data will be presented at the meeting.
- Krazati (adagrasib) / Mirati, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC): Analysis of tumor biomarkers and genomic alterations (Sevilla Auditorium - Hall 9) - Jul 27, 2023 - Abstract #ESMO2023ESMO_303;
P1/2, P3
Conclusions Exploratory analyses suggest diverse mechanisms of acquired resistance in pts treated with ada mono and in combination with cetux, and a greater depth of ctDNA response in pts treated with ada + cetux. Ada + cetux is being investigated in 2L CRC in the phase 3 KRYSTAL-10 trial (NCT04793958).
- HMBD-001 / Hummingbird Biosci
Combining Anti-HER3 Antibody, HMBD-001, with EGFR Inhibition and Chemotherapy may Improve Treatment Outcomes in SqNSCLC (Exhibit Hall) - Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1993;
HMBD-001, a potent anti-HER3 mAb, in combination with EGFR inhibition and chemotherapy, has the potential to greatly improve clinical outcomes following immune-chemotherapy. Hummingbird Bioscience plans to initiate Phase Ib clinical trials in biomarker selected populations of sqNSCLC in H2, 2023.
- Skin Toxicity Associated with Targeted and Immune Therapies in Stage IV Lung Cancer Patients: A 14-year Cohort (Exhibit Hall) - Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1721;
Stg4-NSCLC patients received DoI and experienced Sk-Tox had better treatment response, contributing to better survival outcomes. Oncologists and dermatologists need to effectively collaborate on the awareness, prevention, and treatment of Sk-Tox.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: EMab-300 Detects Mouse Epidermal Growth Factor Receptor-Expressing Cancer Cell Lines in Flow Cytometry. (Pubmed Central) - Jul 25, 2023
Oncologists and dermatologists need to effectively collaborate on the awareness, prevention, and treatment of Sk-Tox. Human EGFR-targeting monoclonal antibody (mAb) therapy such as cetuximab has been approved for clinical use in patients with colorectal cancers and head and neck squamous cell carcinomas...The kinetic analysis using flow cytometry indicated that the K of EMab-300 for CHO/mEGFR and NMuMG was 4.3
- |||| DCC-3116 / Deciphera
New P1/2 trial, Combination therapy, Metastases: A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies (clinicaltrials.gov) - Jul 25, 2023
P1/2, N=170, Not yet recruiting, Sponsor: Deciphera Pharmaceuticals LLC
- ||| nanrilkefusp alfa (SOT101) / Sotio
Enrollment open, Combination therapy: AURELIO-05: A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer (clinicaltrials.gov) - Jul 25, 2023
P2, N=64, Recruiting, Sponsor: SOTIO Biotech AG
Human EGFR-targeting monoclonal antibody (mAb) therapy such as cetuximab has been approved for clinical use in patients with colorectal cancers and head and neck squamous cell carcinomas...The kinetic analysis using flow cytometry indicated that the K of EMab-300 for CHO/mEGFR and NMuMG was 4.3 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Journal, Biopsy: p-mTOR, p-ERK and PTEN Expression in Tumor Biopsies and Organoids as Predictive Biomarkers for Patients with HPV Negative Head and Neck Cancer. (Pubmed Central) - Jul 24, 2023
Also this study shows that the use of HNSCC organoids for biomarker research has potential. The role of PTEN expression as prognostic biomarker remains unclear, as consistent evidence on its prognostic and predictive value is lacking.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: The mechanism of action and biodistribution of a novel EGFR/VEGF bispecific fusion protein that exhibited superior antitumor activities. (Pubmed Central) - Jul 24, 2023
These features resulted in stronger antitumor efficacies in vivo than the combination of bevacizumab and cetuximab. Thus, we provide a promising new strategy for the treatment of EGFR-overexpressing cancers.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Biomarker, Review, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers. (Pubmed Central) - Jul 24, 2023
The phase III BEACON trial made significant progress in the development of BRAF inhibitors by establishing encorafenib-cetuximab as the new standard of care for patients with mCRC who have progressed to one or two previous lines of treatment...There is a crucial need to better understand tumor biology and develop accurate and reliable biomarkers to enhance the antitumor activity of encorafenib-based combinations. The RNF43 mutation is an accurate and reliable predictive biomarker of response, and combinations that target crosstalk between the MAPK pathway, the immune system, and WNT pathways seem promising.
- | Praluent (alirocumab) / Sanofi, Regeneron, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Synthetic Site-Specific Antibody-Ligand Conjugates Promote Asialoglycoprotein Receptor-Mediated Degradation of Extracellular Human PCSK9. (Pubmed Central) - Jul 24, 2023
Interestingly, the alirocumab-tri-GalNAc conjugate was also found to upregulate LDLR levels in comparison with the antibody alone. This study showcases the potential of the targeted degradation strategy against PCSK9 for reducing low-density lipoprotein cholesterol, a risk factor for heart disease and stroke.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Review, Journal, Metastases: The BEETS (JACCRO CC-18) trial: an observational and translational study of BRAF-mutated metastatic colorectal cancer. (Pubmed Central) - Jul 21, 2023
This prospective observational/translational study evaluated real-word clinical outcomes with cetuximab and encorafenib with or without binimetinib for BRAF-mutated mCRC patients and investigated biomarkers for response and resistance by collecting blood samples before and after treatment. Clinical Trial Registration: UMIN000045530 (https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051983).
- || PF-07284892 / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jul 21, 2023
P1, N=196, Recruiting, Sponsor: Pfizer
Clinical Trial Registration: UMIN000045530 (https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051983). Trial completion date: Sep 2026 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Jun 2024
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1/2 trial: Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age (clinicaltrials.gov) - Jul 21, 2023
P1/2, N=20, Not yet recruiting, Sponsor: University of Miami
- | 5-fluorouracil / Generic mfg.
Journal: Preoperative chemotherapy prior to primary tumour resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: The RECUT multicenter randomised controlled trial. (Pubmed Central) - Jul 20, 2023
Trial completion date: Sep 2026 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Jun 2024 For asymptomatic synchronous unresectable CRLMs, Pre-PTR chemotherapy improved the PFS compared with upfront PTR.
- | CIML NK - Dana / Farber Cancer Institute
Trial primary completion date, Combination therapy, Metastases, Immune cell: CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov) - Jul 20, 2023
P1, N=12, Recruiting, Sponsor: Dana-Farber Cancer Institute
For asymptomatic synchronous unresectable CRLMs, Pre-PTR chemotherapy improved the PFS compared with upfront PTR. Trial primary completion date: Jun 2023 --> Sep 2023
- || pegenzileukin (SAR444245) / Sanofi, Innovent Biologics
Trial completion date, Metastases: A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) (clinicaltrials.gov) - Jul 20, 2023
P2, N=280, Active, not recruiting, Sponsor: Sanofi
Trial primary completion date: Jun 2023 --> Sep 2023 Trial completion date: Jan 2024 --> Sep 2023
- | ficlatuzumab (AV-299) / LG Chem, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: P30CA023074: Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 20, 2023
P2, N=78, Completed, Sponsor: University of Arizona
Trial completion date: Jan 2024 --> Sep 2023 N=60 --> 78
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tagrisso (osimertinib) / AstraZeneca, migoprotafib (RLY-1971) / Relay Therap
New P1 trial, Combination therapy, Metastases: Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 20, 2023
P1, N=172, Not yet recruiting, Sponsor: Genentech, Inc.
- ||| rilvegostomig (AZD2936) / AstraZeneca
Enrollment open, Metastases: MERIDIAN: Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC (clinicaltrials.gov) - Jul 20, 2023
P2, N=200, Recruiting, Sponsor: University Health Network, Toronto
N=60 --> 78 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Metastases: Efficacy and Safety of a Parenteral Nutrition Program for Patients with RAS Wild-Type Metastatic Colorectal Cancer Administered First-Line Cetuximab Plus Chemotherapy: A Propensity Score Matching Study. (Pubmed Central) - Jul 18, 2023
Moreover, we noted a significant improvement in the median OS in the same group (53.4 vs. 34.6 months, p = 0.002). Supplemental HPN programs may be recommended for select patients with mCRC receiving targeted therapy plus chemotherapy to improve oncological outcomes.
- | Talzenna (talazoparib) / Pfizer
Journal, BRCA Biomarker, PARP Biomarker: Bispecific antibodies targeting EGFR/Notch enhance the response to talazoparib by decreasing tumour-initiating cell frequency. (Pubmed Central) - Jul 17, 2023
EGFR/Notch bispecific antibodies decrease the subpopulation of stem-like cells, reduce the frequency of tumour-initiating cells, and downregulate mesenchymal gene expression. These findings suggest that combining EGFR and Notch signalling blockade can potentially increase the response to PARP blockade.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P3 trial: Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM (clinicaltrials.gov) - Jul 17, 2023
P3, N=250, Not yet recruiting, Sponsor: Fudan University
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
PK/PD data, Journal, Metastases: Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients. (Pubmed Central) - Jul 14, 2023
P2
This is the first study describing the complex relationship between cetuximab target-mediated pharmacokinetics and PFS in mCRC patients using a joint PK-time-to-progression model. Further studies are needed to provide a more in-depth description of this relationship.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Retrospective data, Journal, Metastases: Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials. (Pubmed Central) - Jul 14, 2023
This pooled analysis including four randomised phase II supports the use of 5-FU/LV plus anti-EGFR as the preferred maintenance regimen. Data provide rational for a more individualised maintenance treatment approach based on tumour and patients features.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Platycodin D represses ?-catenin to suppress metastasis of cetuximab-treated KRAS wild-type colorectal cancer cells. (Pubmed Central) - Jul 14, 2023
Pulmonary metastasis model of HT29 and CaCo2 in nu/nu nude mice consistently showed that combined treatment using platycodin D and cetuximab inhibited metastasis significantly in vivo. Our findings provide a potential strategy to inhibit CRC metastasis during cetuximab therapy by addition of platycodin D.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
Trial completion date, Metastases: S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 12, 2023
P2/3, N=174, Active, not recruiting, Sponsor: SWOG Cancer Research Network
Our findings provide a potential strategy to inhibit CRC metastasis during cetuximab therapy by addition of platycodin D. Trial completion date: Jun 2023 --> Dec 2023
- || TTX-080 / Tizona Therap
Enrollment closed, Trial primary completion date, Combination therapy, Monotherapy, Metastases: TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers (clinicaltrials.gov) - Jul 12, 2023
P1a/1b, N=240, Active, not recruiting, Sponsor: Tizona Therapeutics, Inc
Trial completion date: Jun 2023 --> Dec 2023 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2023 --> Dec 2023
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Metastases: Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series. (Pubmed Central) - Jul 11, 2023
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2023 --> Dec 2023 Cetuximab plus radiotherapy represents an active and tolerable treatment option for laCSCC, including patients with contraindications for checkpoint inhibitor therapy.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, irinotecan / Generic mfg.
EGFR copy number may be important You can treat with cetuximab-folfiri🍀 (Twitter) - Jul 11, 2023
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Osthole inhibits malignant phenotypes and induces ferroptosis in KRAS-mutant colorectal cancer cells via suppressing AMPK/Akt signaling. (Pubmed Central) - Jul 10, 2023
Our results suggested that the natural product osthole exerted its anticancer effects in KRAS-mutant CRC cells via inducing ferroptosis, and this was partially through inhibiting AMPK/Akt/mTOR signaling. Our results may expand our current knowledge for the use of osthole as an anticancer agent.
- Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
EFFECTS OF GUT MICROBIOTA ON ANTITUMOR ACTIVITY IN CHEMOREFRACTORY METASTATIC COLORECTAL CANCER AND NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH CETUXIMAB PLUS AVELUMAB (Poster Stage 1) - Jul 8, 2023 - Abstract #UEGW2023UEGW_1449;
- | Erbitux (cetuximab) / Eli Lilly
Trial primary completion date: Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Jul 6, 2023
P2, N=30, Recruiting, Sponsor: Wake Forest University Health Sciences
Our results may expand our current knowledge for the use of osthole as an anticancer agent. Trial primary completion date: Jun 2023 --> Oct 2023
- || WU-NK-101 / Wugen
Trial initiation date, Combination therapy, Metastases: A Phase 1b Study of WU-NK-101 in Combination With Cetuximab (clinicaltrials.gov) - Jul 6, 2023
P1b, N=30, Not yet recruiting, Sponsor: Wugen, Inc.
Trial primary completion date: Jun 2023 --> Oct 2023 Initiation date: May 2023 --> Nov 2023
- | Libtayo (cemiplimab-rwlc) / Regeneron, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer (clinicaltrials.gov) - Jul 5, 2023
P1, N=30, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Initiation date: May 2023 --> Nov 2023 Trial completion date: Jun 2023 --> Jun 2026 | Trial primary completion date: Jun 2023 --> Jun 2026
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, xevinapant (Debio 1143) / EMD Serono
New P3 trial: XXL_2022-01: Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer (clinicaltrials.gov) - Jul 5, 2023
P3, N=538, Not yet recruiting, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
- || rilvegostomig (AZD2936) / AstraZeneca
Trial completion date, Trial primary completion date, Metastases: MERIDIAN: Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC (clinicaltrials.gov) - Jul 3, 2023
P2, N=200, Not yet recruiting, Sponsor: University Health Network, Toronto
Trial completion date: Jun 2023 --> Jun 2026 | Trial primary completion date: Jun 2023 --> Jun 2026 Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Jul 2026
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Imfinzi (durvalumab) / AstraZeneca
Enrollment change, Trial completion date, Trial primary completion date, Metastases: NRG-HN004: Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin (clinicaltrials.gov) - Jul 3, 2023
P2/3, N=189, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Jul 2026 N=493 --> 189 | Trial completion date: Dec 2025 --> Jun 2024 | Trial primary completion date: Dec 2025 --> Sep 2022
- cyclosporine / Generic mfg.
Treatment of ingrown nails and periungual pyogenic granuloma-like lesions by partial nail avulsion and chemical matricectomy in a patient on cyclosporine treatment due to graft-versus-host disease () - Jul 3, 2023 - Abstract #WCD2023WCD_6189;
Although improper nail trimming appears to be the most common cause, the other causes were reported as poor hygiene, tight-fitting shoes, hyperhidrosis, trauma, and some drugs including epidermal growth factor receptor inhibitors (gefitinib, cetuximab), retinoids, cyclosporine, indinavir, azidothymidine (AZT), fluorouracil (5FU), methotrexate, capecitabine, doxorubicin, and docetaxel...At the time of the submission to our clinic, she has been treated with prednisone and cyclosporine (100 mg/day) for 4 months...Although discontinuation of the drug is needed for the treatment, it may not be possible in every situation due to vital expectations from the drug in cases such as ours. A surgical approach including the removal of the excessive tissue and partial nail avulsion with a matricectomy should be one of the considered approaches in such cases that are unresponsive to conservative treatments